0000000000501271

AUTHOR

De Caro Mf

showing 3 related works from this author

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of th…

2013

ObjectiveTo assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).MethodsPatients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.ResultsOf 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = …

AdultMalemedicine.medical_specialty5 year follow upMultiple SclerosisAdolescentScienceInjections SubcutaneousBrain damageYoung AdultInterferonRecurrenceInternal medicinemedicineHumansIn patientYoung adultCognitive impairmentSex CharacteristicsMultidisciplinarymedicine.diagnostic_testbusiness.industryMultiple sclerosisQRMultiple Sclerosis Subcutaneous interferon β-1a cognitive impairmentMagnetic resonance imagingInterferon-betamedicine.diseaseTreatment OutcomeImmunologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptomSafetybusinessCognition DisordersInterferon beta-1amedicine.drugResearch ArticleFollow-Up Studies
researchProduct

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting …

2010

The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNβ-1a) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (RRMS). Patients aged 18—50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score ≤4.0) were assigned IFNβ therapy at the physician’s discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNβ-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for c…

Maleinterferon beta-1aKaplan-Meier EstimateRelapsing-RemittingNeuropsychological TestsCohort StudiesDisability EvaluationMedicineMale; Adolescent; Young Adult; Middle Aged; Kaplan-Meier Estimate; Cognition Disorders; Survival Analysis; Female; Disability Evaluation; Dose-Response Relationship Drug; Humans; Multiple Sclerosis Relapsing-Remitting; Prospective Studies; Cohort Studies; Disease Progression; Interferon-beta; Injections Subcutaneous; Neuropsychological Tests; Adult; Immunologic Factors; Endpoint DeterminationProspective StudiesProspective cohort studyinterferon beta multiple sclerosis cognitive impairmentSubcutaneousCognitive disorderHazard ratioMiddle AgedSettore MED/26 - NEUROLOGIANeurologyDisease ProgressionSettore MED/26 - NeurologiaFemaleDrugmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentEndpoint DeterminationInjections SubcutaneousLower riskInjectionsDose-Response RelationshipYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicineHumansImmunologic Factorscognitive functioncognitive impairmentExpanded Disability Status ScaleDose-Response Relationship Drugbusiness.industryInterferon beta-1aMcDonald criteriaOdds ratioInterferon-betamedicine.diseaseSurvival AnalysisSurgerydisabilityNeurology (clinical)businessCognition Disorderscognitive function; cognitive impairment; disability; disease progression; interferon beta-1a; multiple sclerosis
researchProduct

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results…

2009

Background Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing–remitting (RR) MS is unclear. Objectives To study the prevalence of cognitive impairment and its relation with MRI disease measures in mildly disabled patients with RRMS. Methods Patients aged 18–50 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale (EDSS) score ≤4.0, who were enrolled in the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study, underwent baseline standardized MRI complete neurological examination and neuropsychological testing. Results…

MalePediatricsIntelligenceRelapsing-RemittingNeuropsychological TestsSeverity of Illness IndexDisability EvaluationCognitionRisk FactorsOdds RatioPrevalenceNeuropsychological assessmentProspective StudiesNeurologic Examinationmedicine.diagnostic_testCognitive impairmet. Cognitive function. Multiple Sclerosis. Neuropsychological assessment.Cognitive disorderNeuropsychologyAge FactorsMiddle AgedMagnetic Resonance ImagingCognitive testTreatment OutcomeNeurologyItalyFemaleSettore MED/26 - NeurologiaPsychologyAdultmedicine.medical_specialtyMultiple SclerosisAdolescentNeurological examinationRisk AssessmentYoung AdultMultiple Sclerosis Relapsing-RemittingPredictive Value of TestsMagnetic Resonance Imaging; Young Adult; Age Factors; Odds Ratio; Immunologic Factors; Humans; Multiple Sclerosis Relapsing-Remitting; Cognition; Italy; Risk Assessment; Adult; Treatment Outcome; Adolescent; Neuropsychological Tests; Male; Severity of Illness Index; Neurologic Examination; Interferon-beta; Predictive Value of Tests; Cognition Disorders; Cross-Sectional Studies; Intelligence; Prospective Studies; Risk Factors; Disability Evaluation; Middle Aged; Female; PrevalencemedicineHumansImmunologic FactorsExpanded Disability Status ScaleMultiple sclerosisMcDonald criteriaInterferon-betamedicine.diseaseCross-Sectional StudiesPhysical therapyNeurology (clinical)Cognition Disorders
researchProduct